Best for Muscle Growth

Creatine monohydrate is one of the most rigorously studied supplements for muscle growth, with consistent evidence from multiple high-quality meta-analyses and RCTs demonstrating significant lean mass gains when combined with resistance training in both younger and older adults.

Ashwagandha demonstrates consistent, clinically meaningful improvements in muscle strength and size in humans during resistance training, supported by multiple well-designed RCTs. Effects on testosterone are modest and inconsistent across populations.

Tesamorelin is a GHRH analog that reliably increases lean body mass and muscle area in HIV-infected adults, with consistent human RCT evidence across multiple independent studies. However, efficacy is primarily demonstrated in the context of HIV-associated lipodystrophy and abdominal obesity; effects in non-HIV populations or as a primary muscle-building agent are less established.

Whey protein supplementation combined with resistance training consistently improves muscle mass and strength in humans across multiple high-quality RCTs and meta-analyses. Effects are modest but real and clinically meaningful, particularly in older adults and when combined with structured exercise.

Beta-alanine has strong evidence for enhancing high-intensity exercise performance lasting 1-4 minutes through increased muscle carnosine buffering, with multiple well-designed human RCTs showing consistent improvements. However, it does NOT directly increase muscle mass or body composition independent of training.

HMB demonstrates strong evidence for increasing muscle mass and strength in humans, supported by multiple meta-analyses and RCTs. Effects are modest but consistent across diverse populations including older adults, athletes, and clinical patients.

Follistatin 344 increases the follistatin/myostatin ratio in humans through resistance training and supplementation interventions, with consistent improvements in muscle strength and mass across multiple RCTs. However, no human study directly administered follistatin 344 as a standalone intervention; all evidence relies on endogenous follistatin elevation via exercise and co-interventions.

Ibutamoren (MK-677) increases IGF-1 levels and shows modest improvements in some functional measures in elderly populations, but evidence for direct muscle growth in humans is limited and inconsistent. Most robust data comes from studies in hip fracture recovery showing functional improvements, though clinical meaningfulness remains debated.

ACE-031 demonstrates probable efficacy for increasing muscle mass and strength in humans, supported by 4 human RCTs showing consistent positive effects on lean body mass and muscle fiber cross-sectional area. However, efficacy is not conclusive due to small sample sizes, short treatment durations, and one trial that was discontinued early due to safety concerns.

Magnesium supplementation shows probable benefits for muscle-related outcomes in older adults and certain athletic populations, with consistent effects on inflammatory markers and some evidence for testosterone elevation, but results are inconsistent across study types and populations, and direct evidence specifically for muscle growth is limited.

Vitamin D3 supplementation shows probable efficacy for muscle growth when combined with resistance training and protein, with modest improvements in lean mass and muscle strength in some studies. However, results are inconsistent across trials, and isolated vitamin D3 without other interventions shows minimal effect on muscle parameters.

Collagen peptides show probable efficacy for muscle growth when combined with resistance training, particularly in elderly/sarcopenic populations. However, evidence is mixed—some RCTs show meaningful gains in lean mass and strength, while others find no additional benefit over placebo for muscle protein synthesis rates.

Probiotics show probable benefits for muscle growth and strength in humans, with meta-analytic evidence demonstrating modest improvements in muscle mass and global muscle strength. However, evidence remains limited to a small number of moderate-quality human RCTs with inconsistent effect sizes and unclear clinical meaningfulness.

Vitamin K2 shows probable efficacy for muscle growth in humans, primarily through improvements in insulin sensitivity and muscle mass in type 2 diabetes patients. Evidence comes from 3 human RCTs with modest sample sizes and short durations, supported by mechanistic studies but lacking large, independently replicated trials.

Urolithin A shows probable efficacy for muscle strength and endurance in humans, with 4 RCTs demonstrating improvements in muscle performance metrics and mitochondrial biomarkers. However, effect sizes are modest, sample sizes small, and results on primary endpoints (like 1RM strength gains) are often non-significant despite improvements in secondary measures.

Epicatechin shows probable efficacy for muscle growth and anti-atrophy effects based on multiple human observational studies and consistent animal data, but robust human RCT evidence is lacking. Results suggest benefits for muscle regeneration, mitochondrial function, and myogenic markers, particularly when combined with exercise.

Ecdysterone demonstrates probable efficacy for muscle growth in humans based on 2 RCTs showing increased muscle mass and strength gains, but evidence is limited by small sample sizes, inconsistent dosing across studies, and lack of independent replication.

Cistanche shows probable efficacy for muscle growth in untrained individuals based on one moderate-quality human RCT, but evidence is limited to a single study with relatively small sample size. Mechanism appears to involve testosterone modulation and cortisol reduction, but human proof is insufficient for strong recommendations.

CLA shows modest, modest effects on body fat reduction in humans (approximately 0.09 kg/week additional fat loss vs placebo at 3.2 g/day), but efficacy is inconsistent across studies and clinically small. Evidence for muscle growth specifically is limited to mechanistic reviews with no direct human RCT data demonstrating lean mass gains.

D-ribose shows probable efficacy for reducing muscle soreness and supporting recovery from intense exercise in humans, with two small RCTs demonstrating positive effects. However, evidence remains limited to small sample sizes and hasn't been independently replicated across multiple research groups.

GABA supplementation shows probable efficacy for muscle growth in humans, with two small RCTs demonstrating increased fat-free mass and growth hormone elevation, supported by multiple animal studies and mechanistic evidence. However, human evidence remains limited to small trials without independent replication.

BCAAs show modest benefits for muscle-related outcomes in athletes and some populations, but evidence is mixed and often confounded by overall protein intake. Human RCT evidence is limited and effect sizes are generally small.

Leucine supplementation consistently activates muscle protein synthesis pathways (mTOR signaling) in humans and increases the fractional synthetic rate of muscle protein. However, long-term studies show mixed results: while it reliably improves protein synthesis markers, it does not consistently translate to greater lean mass or strength gains when added to adequate protein diets or resistance training programs in young, healthy individuals.

BPC-157 shows promising effects for muscle repair in multiple animal studies, but lacks human clinical trials demonstrating proven efficacy for muscle growth.

TB-500 (thymosin β4) shows promising effects for tissue repair and regeneration in animal models, but lacks direct evidence for muscle growth specifically and has minimal human clinical data.

GHK-Cu shows promise for muscle growth and tissue repair in animal models and in vitro studies, but there is no human RCT evidence demonstrating efficacy for muscle growth. Limited observational human data suggests involvement in muscle function in disease states, but efficacy for healthy muscle growth remains unproven.

CJC-1295 reliably increases GH and IGF-1 levels in humans with a long half-life, but no human studies directly measured muscle growth, strength gains, or body composition changes. Efficacy for the specific goal of muscle growth remains unproven in humans.

Ipamorelin stimulates GH secretion and increases bone mineral content in animal models, but no rigorous human efficacy trials for muscle growth exist. Evidence is limited to animal studies, doping control research, and mechanistic investigations.

MOTS-c shows consistent effects on muscle-related outcomes in animal models and limited human observational data, but no human RCTs demonstrate efficacy for muscle growth. Evidence is emerging but not proven in humans.

SS-31 (elamipretide) shows promise for muscle-related conditions in animal models and early human trials, but robust evidence for muscle growth specifically is lacking. Most human data focuses on mitochondrial function and disease states (Barth syndrome, cardiomyopathy) rather than healthy muscle hypertrophy or strength gains.

AOD-9604 is a growth hormone fragment studied primarily for fat loss, not muscle growth. No human studies demonstrate efficacy for muscle growth; one animal study shows lipolytic effects but no muscle-building outcomes. Evidence is insufficient to support muscle growth claims.

Sermorelin increases IGF-1 levels in humans and shows cardiac benefits in animal models of heart disease, but direct evidence for muscle growth in humans is absent. All human data is observational with small samples and no placebo-controlled muscle growth studies.

GHRP-2 robustly stimulates growth hormone secretion in humans and animals, but direct evidence for muscle growth outcomes is limited to one small animal study. Most human evidence focuses on GH release as a diagnostic or mechanistic endpoint rather than actual muscle hypertrophy or strength gains.

GHRP-6 reliably stimulates growth hormone release in humans, but direct evidence for muscle growth is limited to small observational studies and in-vitro work. Animal studies and mechanistic data suggest potential for muscle protein deposition, but no rigorous human RCTs have demonstrated clinically meaningful gains in lean mass or strength.

Hexarelin has not been studied for direct muscle growth in humans. All evidence comes from animal models and mechanistic studies showing potential benefits to muscle health via mitochondrial protection and metabolic improvements, but efficacy for muscle hypertrophy or strength gain remains unproven in human subjects.

Melanotan II shows consistent effects on appetite suppression and energy expenditure in animal models through melanocortin receptor activation, but no human clinical trials for muscle growth exist. All evidence is from rodent studies examining feeding behavior and metabolic pathways, not muscle hypertrophy.

Humanin shows promise for muscle growth through autophagy induction and mitochondrial function improvement in animal and cell studies, but no human RCTs or human efficacy data exist specifically for muscle growth as an endpoint.

GDF-11 has not been proven to promote muscle growth in humans. Most evidence comes from animal studies, mechanistic research, and reviews; human studies show either no association with muscle mass/strength or suggest GDF-11 may actually promote muscle atrophy depending on context.

IGF-1 LR3 shows promise for promoting muscle growth in animal models, with evidence of increased myoblast proliferation and organ growth, but efficacy in humans for muscle growth has not been demonstrated. All human-relevant evidence is limited to fetal or neonatal studies with mixed results.

MGF shows promise for muscle growth based on mechanistic studies and animal models, but lacks rigorous human evidence. Only 2 human RCTs exist in this dataset, and neither directly measured muscle hypertrophy in healthy subjects seeking muscle growth.

GLP-1 receptor agonists effectively promote weight loss and fat mass reduction in humans, but consistently reduce lean muscle mass alongside fat loss, making them poorly suited for the specific goal of muscle growth.

Prostatilen shows consistent effects on tissue regeneration and prostate health markers in animal models, but there is no human evidence demonstrating efficacy for muscle growth specifically. All evidence is limited to rodent studies.

Omega-3 supplementation shows plausible benefits for muscle health through anti-inflammatory and anabolic mechanisms, but human evidence is inconsistent and largely negative for direct effects on muscle mass and strength gains. Multiple meta-analyses and systematic reviews find no significant effect on lean body mass or protein synthesis.

NAC has not been proven effective for muscle growth in humans. While one small human RCT and several animal studies suggest NAC may support myoblast differentiation and prevent muscle damage under specific conditions, there is no direct evidence that NAC promotes muscle hypertrophy or strength gains in healthy populations.

Zinc shows plausible but unproven efficacy for muscle growth in humans. Evidence is primarily mechanistic (via testosterone and protein metabolism) supported by animal studies, but direct human evidence linking zinc supplementation to increased muscle mass or strength is absent from the abstracts provided.

Berberine has not been studied for direct muscle growth in humans. All evidence concerns metabolic and glucose regulation effects, with no RCTs demonstrating effects on muscle mass, strength, or hypertrophy.

Curcumin has not been adequately studied for direct muscle growth in humans. While meta-analyses show it reduces muscle damage markers (CK, soreness) post-exercise and improves inflammatory/oxidative profiles, no human RCTs directly measure muscle hypertrophy, strength gains, or lean mass accumulation — the actual endpoints for muscle growth.

Quercetin has been extensively studied for muscle growth and exercise performance, but the evidence does not demonstrate clinically meaningful benefits for muscle hypertrophy. Human studies show modest improvements in endurance capacity and VO2max in untrained individuals, but no proven effect on muscle mass, strength, or body composition.

NMN shows plausible mechanisms for muscle-related benefits through NAD+ restoration and metabolic optimization, but direct evidence for muscle growth in humans is absent. The limited human data focuses on insulin sensitivity and aerobic capacity rather than hypertrophy or strength gains.

Alpha-lipoic acid has not been demonstrated to promote muscle growth in humans. While some studies show metabolic benefits (weight loss, insulin sensitivity, antioxidant effects), there is no direct evidence that ALA increases muscle mass, strength, or lean body mass in any of the 50 available studies.

Tongkat Ali shows plausible effects on testosterone levels in aging men and hypogonadal populations based on small human RCTs and observational studies, but evidence for direct muscle growth is absent. No human studies measuring lean mass, strength, or hypertrophy outcomes were identified in this set.

Boron supplementation shows plausible mechanisms for muscle/strength development through testosterone modulation and bone metabolism enhancement, but human evidence for direct muscle growth is absent or negative. Available human RCTs in bodybuilders found no significant effect on lean body mass or strength despite adequate boron absorption.

Rhodiola rosea has not been directly studied for muscle growth in human trials. Limited animal data suggests potential benefits when combined with resistance exercise, but no evidence of efficacy specific to muscle hypertrophy exists in humans.

Maca root shows promise for muscle growth and physical performance in animal models and has bioactive compounds with antioxidant and anti-inflammatory properties, but human evidence for muscle growth specifically is absent. Clinical trials have focused on sexual function and fertility, not muscle hypertrophy.

Green tea extract (EGCG) shows mechanistic promise for muscle health through antioxidant and anti-inflammatory pathways, but has virtually no direct human evidence for muscle growth. One small animal study demonstrated increased muscle mass in a sarcopenia model, but this falls far short of proving efficacy in healthy individuals seeking muscle hypertrophy.

Spirulina shows promise for muscle-related outcomes in elite athletes and during weight loss, but evidence is limited to 3 small human RCTs with inconsistent primary efficacy measures. Most data comes from animal studies or mechanistic reviews without direct muscle growth endpoints.

Fenugreek shows no demonstrated efficacy for muscle growth in humans. The available evidence focuses on testosterone elevation and metabolic effects, but lacks any direct assessment of lean muscle mass, strength gains, or muscle hypertrophy.

Vitamin C shows plausible mechanisms for muscle growth through collagen synthesis, carnitine biosynthesis, and epigenetic regulation of myogenesis, but human RCT evidence demonstrates it does NOT enhance muscle hypertrophy during resistance training and may actually blunt certain adaptations.

Vitamin B Complex shows plausible mechanisms for supporting exercise performance and energy metabolism, but direct evidence for muscle growth is largely absent. One human RCT demonstrated improved running endurance and reduced blood lactate with B vitamin supplementation, but no studies specifically measured muscle hypertrophy or protein synthesis as primary outcomes.

Vitamin E supplementation shows no proven benefit for muscle growth or recovery in humans. Meta-analyses of human RCTs consistently demonstrate null effects on muscle strength, soreness, and damage markers despite theoretical antioxidant mechanisms.

Iron supplementation improves exercise performance and oxygen consumption in women with iron deficiency, and shows promise for muscle function in specific disease models (CKD, muscular dystrophy). However, no human RCTs specifically measuring muscle growth (hypertrophy, strength gains) exist; evidence is limited to aerobic performance metrics and animal models of muscle pathology.

Selenium supplementation shows plausible mechanisms for supporting muscle growth and antioxidant protection in skeletal muscle, supported primarily by animal studies and mechanistic research. However, no human RCTs directly demonstrate that selenium supplementation increases muscle mass or strength in healthy individuals seeking muscle growth.

Chromium has not been proven effective for muscle growth in humans. While one small human RCT showed a trend toward increased muscle protein synthesis when combined with whey protein and carbohydrates, the primary evidence base consists of studies on glucose metabolism and metabolic health in diabetic populations, not muscle hypertrophy or athletic performance.

Spermidine shows mechanistic promise for muscle health through autophagy activation and mitochondrial support, but direct evidence for muscle growth in humans is absent. Only one animal study (COL6-deficient mice) demonstrates functional muscle strength improvements, and the single human RCT examined bioavailability, not muscle outcomes.

Sulforaphane shows promise for muscle growth primarily through animal studies demonstrating increased muscle fiber size and activation of anabolic signaling pathways. However, evidence in humans is extremely limited, consisting of only one small observational study, making efficacy in human muscle growth unproven.

Astaxanthin has been studied for muscle growth and recovery in humans, but the evidence shows mixed and mostly negative results. While animal studies suggest protective effects against muscle atrophy, human RCTs consistently fail to demonstrate meaningful benefits for muscle damage, recovery, or growth metrics.

Glutathione supplementation shows promise for muscle-related outcomes in limited human studies, primarily through improved exercise recovery and aerobic metabolism. However, evidence is sparse and mixed, with most data coming from small pilot studies or animal models rather than large-scale human trials designed specifically to measure muscle growth.

Shilajit has not been proven to directly enhance muscle growth in humans. Only one human RCT exists, which measured skin gene expression and perfusion rather than muscle mass or strength outcomes. Five animal studies suggest potential mechanisms (mitochondrial function, antioxidant activity, testosterone modulation) but do not directly demonstrate muscle hypertrophy.

Bovine colostrum shows limited efficacy for muscle growth in humans. While one RCT demonstrated improved lower body power (vertical jump), multiple studies found no significant effects on strength, muscle mass, or anabolic hormones, and one mechanistic study showed increased both protein synthesis and breakdown without net benefit.

Cordyceps shows promise for muscle growth and weight gain in animal models, with one study demonstrating increased average daily weight gain in weaned pigs at 100 mg/kg supplementation. However, no human RCTs exist for this goal, and the mechanism appears indirect (improved nutrient absorption and intestinal health rather than direct muscle protein synthesis).

Apigenin shows promising effects on skeletal muscle growth in animal models through activation of Prmt7 and mTORC1 pathways, but evidence is limited to rodent studies with no human clinical trials demonstrating efficacy for muscle growth.

Pomegranate extract shows promise for muscle-related outcomes through increased IGF-1 levels and improved exercise recovery in animal and small human studies, but direct evidence for muscle growth in humans is limited and indirect. Most robust findings relate to antioxidant and anti-inflammatory effects that support exercise recovery rather than muscle hypertrophy itself.

Olive leaf extract shows plausible mechanisms for muscle metabolism and mitochondrial function in humans, but no direct evidence of muscle growth or hypertrophy has been demonstrated. Available human data is limited to metabolic markers and strength measures with inconsistent results.

MSM shows promise for exercise recovery and reducing oxidative stress markers in human studies, but there is no demonstrated efficacy for direct muscle growth. Evidence is limited to small human RCTs (n<25) focused on muscle damage recovery rather than hypertrophy.

Bromelain shows promise for muscle recovery and reducing exercise-induced muscle damage in humans, but evidence remains limited to a single small RCT (n=15) with indirect markers. No studies directly demonstrate increased muscle growth, strength gains, or hypertrophy.

Mucuna pruriens has not been proven effective for muscle growth in humans. While some animal studies suggest potential anabolic effects through testosterone elevation, no human RCTs specifically testing muscle growth outcomes exist, and available human data focuses on fertility and semen parameters rather than skeletal muscle development.

Turkesterone shows consistent anabolic effects on protein synthesis in animal models, but zero human RCT evidence exists for muscle growth. A single 2024 preliminary human study found non-significant increases in IGF-1 and resting metabolic rate, failing to support turkesterone as a potent anabolic supplement.

Tribulus terrestris does not meaningfully enhance muscle growth or strength in humans. While some animal studies suggest potential mechanisms, human RCTs consistently show no improvements in body composition, muscle mass, or resistance training performance.

Echinacea has not been proven effective for muscle growth in humans. Limited human RCT data shows potential effects on erythropoietin and running economy, but these are indirect markers of athletic performance, not direct measures of muscle hypertrophy or strength gains.

Valerian root has not been proven effective for muscle growth in humans. One animal study suggests it may prevent glucocorticoid-induced muscle atrophy, but all other evidence focuses on sleep and anxiety, not muscle development.

Schisandra shows promise for muscle growth primarily through animal studies demonstrating activation of IGF-1/Akt/mTOR pathways and reduction of muscle atrophy markers, but no human RCTs exist to prove efficacy in humans. Evidence is emerging but not yet clinically validated.

Rapamycin inhibits mTOR signaling and suppresses muscle protein synthesis in humans, which is mechanistically opposite to the goal of muscle growth. While some animal studies suggest potential compensatory hypertrophic responses in specific contexts (cardiac/podocyte), human evidence indicates rapamycin reduces muscle protein synthesis and poses risks for muscle loss, particularly in older populations.

Astragalus shows promise for muscle growth and recovery in animal models through anti-inflammatory and antioxidant mechanisms, but human efficacy for muscle growth is not yet established. Only one human study specifically addresses muscle-related outcomes (denervation-induced atrophy), and the evidence base lacks direct human RCTs examining muscle hypertrophy or strength gains.

Butyrate shows plausible mechanisms for muscle health in animal models and limited human observational data, but no human RCTs directly demonstrate efficacy for muscle growth. Evidence is largely mechanistic rather than outcome-based.

Forskolin has been studied for muscle growth primarily in multi-ingredient supplement formulations rather than as an isolated compound. Evidence is limited to 2 human RCTs (both with confounding multi-ingredient designs) and lacks direct, rigorous demonstration of efficacy for muscle growth in humans.

Betaine supplementation shows modest improvements in athletic performance and some anabolic signaling markers in humans, but fails to improve muscle hypertrophy, body composition, or muscle strength in controlled trials. Evidence remains preliminary and inconsistent for muscle growth as a primary goal.

Phosphatidylserine has been studied primarily for muscle recovery and regeneration mechanisms rather than direct muscle growth. One human RCT found no protective effect against exercise-induced muscle damage, while most evidence consists of mechanistic reviews describing PS's role in cell signaling and muscle regeneration processes.

Phenylpiracetam has not been studied for muscle growth in humans. Animal studies show indirect benefits (reduced body weight gain, improved metabolic markers, anti-inflammatory effects) but no direct evidence of increased muscle mass or strength.

Bromantane/ladasten shows consistent effects on dopamine signaling and stress adaptation in animal models and a single small human RCT, but direct evidence for muscle growth in humans is absent. The compound appears to enhance physical performance and fatigue tolerance, but these are not equivalent to proven anabolic effects on muscle tissue.

L-theanine has not been demonstrated to promote muscle growth in humans. While animal studies show muscle fiber type shifts and some metabolic changes, there are no human RCTs examining muscle hypertrophy, strength gains, or muscle protein synthesis as primary outcomes.

Glycine supplementation shows promise for muscle growth and recovery in animal models and limited human studies, with plausible mechanisms via ferroptosis resistance and creatine synthesis, but efficacy in humans for muscle hypertrophy remains unproven and understudied.

5-HTP shows plausible effects on body composition in one small human RCT (fat mass reduction), but efficacy for muscle growth is not proven. Most evidence comes from animal studies and mechanistic research, with no human data demonstrating direct muscle hypertrophy.

L-Citrulline's effects on muscle growth remain unproven in humans. While it improves nitric oxide bioavailability and vascular function, the largest meta-analysis found no substantial effects on fat-free mass, body weight, or body composition overall.

Taurine shows plausible mechanisms for muscle support through antioxidant and calcium regulation pathways, but lacks direct human RCT evidence demonstrating efficacy for muscle growth. Available human data is limited to observational associations and indirect cardiovascular/metabolic effects.

D-aspartic acid has not been proven effective for muscle growth in humans. While mechanistic reviews suggest potential benefits for testosterone production and testicular function, the limited human RCT evidence shows null or negative results for testosterone and athletic performance.

L-carnosine has not been studied for muscle growth in humans. Animal studies show modest improvements in growth metrics, but the evidence base consists primarily of mechanistic reviews and a single animal study with muscle-growth endpoints; no human efficacy trials for this specific goal exist.

L-arginine supplementation shows consistent positive effects on muscle growth and development in animal models, but human evidence is extremely limited. Only 2 human RCTs exist among 50 total articles, and neither directly measured muscle hypertrophy as a primary outcome.

Ornithine has been studied in humans for fatigue and stress relief, but NO studies in these abstracts directly examine muscle growth. The evidence is emerging for fatigue mitigation through metabolic pathways, but efficacy for the stated goal of muscle growth is not demonstrated.

L-serine shows neuroprotective effects in animal models of ischemic stroke and neuronal injury, but evidence for muscle growth specifically is absent from the provided literature. The compound has not been studied for muscle hypertrophy or strength gains in humans or animals.

CJC-1295 DAC has not been tested for efficacy on muscle growth in humans. The only available study is an in-vitro detection method for anti-doping purposes and provides no evidence of actual biological effects or safety.

PT-141 has not been studied for muscle growth in humans or animals. All available evidence concerns sexual dysfunction treatment; the compound's effects on muscle tissue are entirely unexplored.

Epithalon has not been studied for muscle growth in humans or animals. All evidence is mechanistic (gene regulation, chromatin reactivation, antioxidant effects) or concerns aging-related systemic effects unrelated to skeletal muscle hypertrophy or strength.

KPV has NOT been studied for muscle growth in humans or animals. All evidence focuses on anti-inflammatory and wound-healing effects in tissues unrelated to skeletal muscle hypertrophy or strength.

Thymosin Alpha-1 has not been studied for muscle growth in any of the available literature. All identified research focuses on immune modulation, cancer, infection, and inflammatory conditions — not skeletal muscle hypertrophy or athletic performance.

LL-37 has NOT been demonstrated to promote muscle growth in any of the 50 available abstracts. Instead, evidence shows LL-37 functions primarily as an antimicrobial and immunomodulatory peptide involved in wound healing, infection control, and inflammation—with no human or animal studies reporting effects on skeletal muscle hypertrophy or strength gains.

Dihexa has not been studied for muscle growth in humans or animals. All available evidence focuses on cognitive and neuroprotective effects in neurodegenerative disease models; efficacy for muscle growth is entirely unproven.

Kisspeptin has been extensively studied for reproductive function, but there is no evidence in these abstracts that it promotes muscle growth. The compound's role is limited to regulating reproductive hormones and metabolism, with no studies directly assessing muscle hypertrophy, protein synthesis, or strength outcomes.

FOXO4-DRI has not been studied for muscle growth in humans or animals. All available evidence focuses on senescent cell clearance in contexts like pulmonary fibrosis, cancer, and aging-related disorders—mechanisms unrelated to skeletal muscle hypertrophy or strength gains.

VIP has not been studied for muscle growth in humans or animals. The 20 most relevant abstracts focus on VIP's roles in neurological function, pulmonary hypertension, reproductive hormones, and neuromodulation—none examine skeletal muscle hypertrophy or strength gains.

Thymalin has not been studied for muscle growth in any of the 46 available abstracts. All evidence relates to immune function, infections, and age-related diseases. No efficacy data exists for this compound as a muscle-building agent.

Pinealon has not been studied for muscle growth in humans or animals. All evidence concerns neuroprotection, antioxidant activity, and aging-related outcomes in brain tissue and systemic aging markers. No studies assessed muscle hypertrophy, strength, or muscle protein synthesis.

Cortagen has not been studied for muscle growth in any of the available literature. All 6 abstracts examine neuroprotective, immunomodulatory, and antioxidant effects in animal models, with zero relevance to skeletal muscle hypertrophy or strength development.

Cardiogen has not been studied in humans for muscle growth. Available evidence is limited to two small animal studies and one in vitro study showing effects on cardiac tissue proliferation, with no relevance to skeletal muscle growth.

Chonluten has only in-vitro evidence showing it modulates inflammatory pathways in human monocyte cell lines. No human trials, animal studies, or efficacy data for muscle growth exist.

Vilon (Lys-Glu dipeptide) has not been studied for muscle growth in humans or animals. All available evidence focuses on immune function, aging, and gene expression in non-muscle tissues; no efficacy for muscle growth has been demonstrated.

Bronchogen has not been studied for muscle growth in any available research. All identified studies examine its effects on lung tissue repair and bronchial epithelium in COPD models or cell cultures—a completely different health goal.

Cartalax has not been studied for muscle growth in any of the available literature. All 6 abstracts focus on cellular aging, regeneration, and differentiation in non-muscle tissues (thymus, kidney, skin, neural, bone marrow stem cells), with zero human trials and no relevance to skeletal muscle hypertrophy.

5-Amino-1MQ has not been studied for muscle growth in humans or animals. Available evidence focuses exclusively on cancer immunotherapy, obesity/weight loss, and cancer cell proliferation—none of which directly assess muscle tissue growth or hypertrophy.

ARA-290 has not been studied for muscle growth in humans. All evidence is limited to animal models and cell culture showing tissue-protective and anti-inflammatory effects, with no direct demonstration of muscle hypertrophy or strength gains.

Cerebrolysin has been studied exclusively for stroke recovery, traumatic brain injury, and neurodegenerative diseases—not for muscle growth. No human or animal studies in the provided abstracts demonstrate any effect on skeletal muscle hypertrophy, strength, or muscle protein synthesis.

Oxytocin has not been studied for muscle growth in humans, and available evidence does not demonstrate efficacy for this goal. The 32 identified abstracts focus on social behavior, autism, anxiety, reproductive function, and appetite regulation—not skeletal muscle hypertrophy or strength.

Argireline has not been studied for muscle growth in any of the identified literature. All available evidence concerns skin aging, collagen synthesis, and anti-wrinkle effects in skin cells and aged mice—not skeletal muscle hypertrophy or athletic performance.

Decapeptide-12 has no demonstrated efficacy for muscle growth. The only available study is an in-vitro investigation of skin penetration for hyperpigmentation treatment, which is completely unrelated to muscle growth.

Retinalamin has not been studied for muscle growth in humans or animals. The available evidence focuses exclusively on retinal/ocular health, hemostasis, and antioxidant effects unrelated to skeletal muscle.

Resveratrol has not been demonstrated to promote muscle growth in humans. The limited human evidence shows metabolic effects (improved insulin sensitivity, reduced inflammation) and one observational study in heart failure mice showing improved exercise capacity, but no studies document increases in muscle mass, strength, or hypertrophy as a primary outcome.

CoQ10 has not been studied for muscle growth in any of the 50 identified abstracts. The literature focuses exclusively on oxidative stress, mitochondrial function, cardiovascular disease, fertility, and neurological conditions—not skeletal muscle hypertrophy or strength gains.

Melatonin has no demonstrated efficacy for muscle growth in humans. The available evidence focuses almost entirely on melatonin's antioxidant, anti-inflammatory, and circadian rhythm effects in disease states, with zero human RCTs or observational studies measuring muscle growth, strength, or lean mass as primary outcomes.

Milk thistle has not been demonstrated to promote muscle growth in any human or animal studies. All identified research focuses on liver health, metabolic effects, and antioxidant properties—none assess muscle hypertrophy, strength gain, or lean mass development.

Black seed oil has not been studied for muscle growth in humans. All evidence comes from mechanistic studies on inflammation and oxidative stress, which are tangentially related to muscle recovery but do not demonstrate direct effects on muscle hypertrophy, strength, or athletic performance.

Elderberry has not been studied for muscle growth in humans or animals. The 50 available PubMed abstracts focus on immune function, antioxidant effects, anti-inflammatory properties, and neuroprotection—not skeletal muscle hypertrophy or strength gains.

Aged garlic extract has not been studied for muscle growth in humans. All available evidence focuses on cardiovascular health, immune function, and neuroprotection; no abstracts demonstrate efficacy for skeletal muscle hypertrophy or strength gains.

Psyllium husk has been extensively studied for metabolic and gastrointestinal health, but there is no evidence in the available literature demonstrating efficacy for muscle growth. The compound's mechanisms relate to glucose control, lipid metabolism, and microbiota modulation—none of which directly support skeletal muscle hypertrophy.

Saw palmetto has been studied extensively for benign prostatic hyperplasia and hair loss, but there is no credible evidence it promotes muscle growth. The abstracts provided contain zero studies investigating saw palmetto's effects on muscle development, strength, hypertrophy, or lean mass.

Glucosamine + Chondroitin has not been studied for muscle growth in humans. The evidence available focuses exclusively on osteoarthritis and joint health, with no direct efficacy data supporting use for muscle hypertrophy or strength gain.

Vitamin B12 has not been studied for muscle growth in any of the 50 available abstracts. All relevant human evidence addresses neuropathy, metabolic markers, and other non-muscle outcomes. No efficacy for muscle growth is demonstrated or even addressed.

Copper supplementation has NOT been proven to enhance muscle growth in humans. The 50 articles focus on copper's role in enzymatic function, neurological disease, bone metabolism, and general growth in animals and fish — but virtually no human evidence demonstrates that copper supplementation builds muscle mass or improves strength.

Fisetin has not been studied for muscle growth in humans or animals. All available evidence concerns unrelated health goals (neuroprotection, senescence, inflammation, cancer), making efficacy for muscle growth unproven and unsupported by the current literature.

DIM has not been studied for muscle growth in humans or animals. All available evidence focuses on estrogen metabolism, cancer prevention, and reproductive effects — outcomes unrelated to skeletal muscle hypertrophy or strength gains.

Boswellia has been extensively studied for osteoarthritis and inflammatory conditions, but there is no credible evidence it promotes muscle growth. All human studies focus on joint pain, inflammation, and mobility—not lean mass or strength gains.

TUDCA has not been studied for muscle growth in humans or animals. While TUDCA shows promise for ER stress reduction and cellular protection across multiple conditions, there is no evidence in the provided abstracts demonstrating efficacy for muscle growth, hypertrophy, or strength gains.

Nattokinase has not been studied for muscle growth in humans or animals. All available evidence focuses on cardiovascular, thrombolytic, neuroprotective, and metabolic effects; zero studies demonstrate efficacy for muscle hypertrophy or strength gains.

Beta-glucans have not been studied for muscle growth in humans. The available literature exclusively focuses on immune function, infection resistance, and inflammation—not skeletal muscle hypertrophy, strength gains, or athletic performance.

Reishi has not been studied for muscle growth in any human trials. All available research focuses on other health goals (gastric protection, cancer, obesity, inflammation, etc.), with no evidence demonstrating efficacy for muscle growth even in animal models.

No human evidence exists that Chaga mushroom promotes muscle growth. All relevant studies focus on anti-cancer, anti-inflammatory, and antioxidant effects unrelated to skeletal muscle hypertrophy or strength development.

Pterostilbene has not been studied for muscle growth in humans. All available evidence consists of in-vitro and animal studies focused on unrelated health conditions (cancer, inflammation, fibrosis, melanogenesis). There is no evidence of efficacy for muscle growth at any dose.

Grape seed extract has not been studied for muscle growth in humans. All relevant evidence comes from animal models (pigs, eels, rats) examining indirect markers like muscle composition and lipid metabolism, with no human trials demonstrating effects on muscle hypertrophy, strength, or protein synthesis.

Lactoferrin has NOT been demonstrated to improve muscle growth in any human studies. The 36 available abstracts focus on iron metabolism, immune function, infections, and brain health—not muscle development or performance.

Stinging nettle has not been studied for muscle growth in humans. The 50 PubMed articles focus on diabetes, cancer, viral infections, and other health conditions—not skeletal muscle hypertrophy or athletic performance.

Fadogia agrestis has not been studied for muscle growth in humans or animals. All four available studies examine sexual function, erectile dysfunction, testicular function, or organ toxicity—not skeletal muscle development or hypertrophy.

Passionflower has not been studied for muscle growth in humans or animals. All evidence relates to anxiety, depression, stress, and neurological outcomes—goals entirely unrelated to skeletal muscle hypertrophy or strength development.

Lemon balm has not been studied for muscle growth in humans or animals. All 50 articles focus on cognitive, mood, metabolic, dermatological, and anti-inflammatory effects—not skeletal muscle hypertrophy or strength.

Lithium orotate has not been studied for muscle growth in any of the 26 available abstracts. All evidence concerns neuroprotection, cognitive function, seizure management, and mood disorders—none of which translate to proven efficacy for muscle hypertrophy or strength gains.

No human trials of pregnenolone for muscle growth exist in this literature. All evidence is mechanistic or biochemical in nature, describing how pregnenolone functions as a steroid precursor in androgen synthesis pathways, without any studies demonstrating clinical efficacy for muscle growth in humans or animals.

Hyaluronic acid has not been studied for muscle growth in humans or animals. All available evidence concerns skin health, joint lubrication, cartilage health, and eye disease — not skeletal muscle development or hypertrophy.

Peppermint oil has been extensively studied for irritable bowel syndrome, but there is no credible evidence it promotes muscle growth. All identified abstracts concern GI health, not skeletal muscle development or strength gains.

Lion's Mane has not been studied for muscle growth in humans. All evidence is mechanistic (NGF stimulation, neuroprotection) or concerns unrelated health domains (cognition, mood, immunity, cancer). No human or animal studies demonstrate efficacy for muscle hypertrophy or strength gain.

Alpha-GPC has been extensively studied for cognitive function and neuroprotection, but there is NO evidence in the provided abstracts demonstrating efficacy for muscle growth. All relevant human and animal studies focus on cognitive, neurological, or reproductive outcomes.

Bacopa monnieri has not been studied for muscle growth in humans or animals. All available evidence focuses on neuroprotection, cognitive function, and neurodegenerative disease treatment, with zero relevance to skeletal muscle hypertrophy or strength adaptation.

CDP-choline has not been studied for muscle growth in humans. Available evidence is limited to mechanistic reviews and studies in non-muscle contexts (liver metabolism, neurodegeneration, inflammatory bowel disease), with no direct evidence of efficacy for muscle hypertrophy or strength gain.

Ginkgo biloba has not been studied for muscle growth in humans. The only direct evidence comes from a single in-vitro study showing that ginkgolic acid (a component of Ginkgo) actually INHIBITS myoblast proliferation and myotube formation—the opposite of muscle growth.

Panax ginseng has not been studied for muscle growth in any of the 50 available abstracts. The evidence is entirely absent for this specific goal, despite extensive research on ginseng's effects in other domains.

Huperzine A has not been studied for muscle growth in humans or animals. The available evidence concerns only cognitive/neurological effects (Alzheimer's disease, depression, epilepsy), and no abstracts report any findings relevant to skeletal muscle hypertrophy or strength gains.

PQQ has not been studied for muscle growth in humans. The only human RCT examining exercise performance found no significant differences in aerobic outcomes between PQQ and placebo, despite increased mitochondrial biomarkers in the PQQ group.

Noopept has no demonstrated efficacy for muscle growth. All relevant studies examine cognitive, neuroprotective, or metabolic effects in rodent models; none assess muscle growth, strength, or lean mass as primary or secondary outcomes.

Piracetam has not been studied for muscle growth in humans or animals. All retrieved abstracts address cognitive, neuroprotective, or neurological effects in brain tissue, with no relevance to skeletal muscle development, protein synthesis, or body composition.

Aniracetam has no demonstrated efficacy for muscle growth in humans or animals. The compound is studied exclusively for cognitive and neuroprotective effects; no abstracts report any effects on muscle mass, strength, or hypertrophy.

Uridine has not been studied for muscle growth in humans. The abstracts discuss uridine's roles in nucleotide synthesis, mitochondrial function, and disease treatment, but contain no evidence of efficacy for muscle growth or hypertrophy.

Vinpocetine has not been studied for muscle growth in any of the 50 available abstracts. All evidence concerns cerebrovascular protection, neuroprotection, and blood flow enhancement—entirely unrelated to skeletal muscle hypertrophy or strength development.

9-ME-BC has not been studied for muscle growth in humans or animals. All available evidence concerns dopaminergic neuroprotection and cognitive effects in brain tissue; no abstracts address skeletal muscle hypertrophy, strength gains, or muscle-related outcomes.

No human evidence supports fasoracetam for muscle growth. The only human RCT evaluated ADHD outcomes, not muscle development, and the second study was a pharmaceutical chemistry review with no efficacy data.

Oxiracetam has not been studied for muscle growth in any of the available human or animal research. All evidence is limited to neuroprotection, cognitive function, and brain injury recovery.

L-tyrosine has not been proven effective for muscle growth in humans. Available evidence consists primarily of mechanistic studies, metabolomic analyses, and a single small observational case series in nemaline myopathy patients showing anecdotal improvements—not rigorous efficacy data for healthy muscle development.

L-Glutamine supplementation has not been proven effective for muscle growth in humans. The available evidence consists primarily of mechanistic reviews and studies focused on gut health, immune function, and disease states—not muscle hypertrophy or strength gains.

Acetyl-L-Carnitine has not been demonstrated to improve muscle growth in humans. The single relevant human RCT (trained cyclists) showed no improvement in anaerobic or aerobic performance despite 4 weeks of supplementation, and bioavailability concerns severely limit practical efficacy.

Tryptophan supplementation has not been proven effective for muscle growth in humans. Evidence is limited to mechanistic studies of tryptophan metabolism and stress/mood effects, with no direct evidence of muscle hypertrophy or strength gains.

Lysine has not been demonstrated to promote muscle growth in humans. The single relevant human RCT found no effect on growth hormone or insulin levels in weightlifters, and most reviewed studies address unrelated health conditions (vision, liver disease, IBS) rather than muscle development.